Website profile

Pharmaceutical Executive

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

  • 913articles · 365d
  • 4+ hour agolatest article
  • Sep 14, 2025earliest in window
  • 95%with images
  • 285avg words
articles per day
Categories
  • Medical 573
  • Business & Industrial 538
  • Economy, Business & Finance 451
  • Health & Wellness 337
  • Health 267
  • Finance & Business 254
  • Science & Technology 156
  • Science & Nature 42

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

PharmExec
pharmexec.com > view > boards-ai-500-years-experience-life-sciences-takeaways-board-forum

Boards, AI, and 500 Years of Experience in Life Sciences: Takeaways from the 2026 Life Sciences Board Forum

4+ hour, 40+ min ago   (92+ words) This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr... Ten life sciences board directors on AI's three hardest questions: developing the…...

PharmExec
pharmexec.com > view > daily-moonwalk-biosciences-70-million-series-b

Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B

4+ day, 3+ hour ago   (83+ words) Moonwalk Biosciences' $70 Million Series B | PharmExec Pharmaceutical Executive Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks…...

Pharmaceutical Executive
pharmexec.com > shorts > persistent-unmet-needs

Exec on Execs: Persistent Unmet Needs | PharmExec

5+ day, 17+ hour ago   (56+ words) Exec on Execs: Persistent Unmet Needs Pharmaceutical Executive Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq How New Therapies…...

Pharmaceutical Executive
pharmexec.com > shorts > pharma-50-the-trends-behind-the-numbers

Pharma 50: The Trends Behind the Numbers | PharmExec

1+ week, 16+ hour ago   (89+ words) Explore the key storylines and hot-topic issues shaping Pharm Exec’s recently published “Pharma 50” company rankings, our annual leaderboard of the top global biopharma organizations measured by prescription drug sales. For more analysis, data, and expert insight on the trends highlighted…...

Google News
pharmexec.com > view > -fda-review-process-patients-provider-watching

What Moments in FDA???s Review Process Should Patients and Providers be Watching Closely?

1+ week, 2+ day ago   (259+ words) What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely? Pharmaceutical Executive Nate Hill, Co-Founder & CEO of Strive Pharmacy, outlines the key milestones in the FDA's review process that both patients and providers should be tracking as…...

PharmExec
pharmexec.com > view > daily-novartis-bms-halt-car-t-trials

Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials

1+ week, 3+ day ago   (566+ words) Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and…...

PharmExec
pharmexec.com > view > daily-haisco-licenses-immunology-asset--sentivera

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

2+ week, 3+ day ago   (497+ words) Haisco Licenses Preclinical Immunology Asset to Sentivera | PharmExec Pharmaceutical Executive Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike…...

PharmExec
pharmexec.com > view > moving-beyond-sample-size-guess-lessons-60-million-clinical-trial-simulations

Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations

2+ week, 3+ day ago   (118+ words) Pharmaceutical Executive Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk. Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your…...

PharmExec
pharmexec.com > view > daily-amplitude-therapeutics-partners-eli-lilly

Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly

3+ week, 1+ day ago   (469+ words) Amplitude Therapeutics Partners with Eli Lilly | PharmExec Pharmaceutical Executive...

PharmExec
pharmexec.com > view > your-questions-answered-rare-disease-specialty-drug-news-tells-us-about-where-industry-heading

Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading

3+ week, 1+ day ago   (80+ words) Pharmaceutical Executive Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and…...